Lack of reproducibility of assessment of aspirin responsiveness by optical aggregometry and two platelet function tests

Platelets

Volumn 19, Issue 2, 2008, Pages 119-124

  Harrison, Paul ^a   Segal, Helen ^b   Silver, Louise ^b   Syed, Anila ^b   Cuthbertson, Fiona C ^b   Rothwell, Peter M ^b  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Aggregometry; Aspirin; PFA 100 ; Platelet; VerifyNow aspirin

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CYCLOOXYGENASE 1;

ARTICLE; BLOOD CLOTTING PARAMETERS; BLOOD SAMPLING; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG RESPONSE; ENZYME ACTIVITY; FOLLOW UP; HUMAN; KAPPA STATISTICS; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; REPRODUCIBILITY; RISK FACTOR; STATISTICAL SIGNIFICANCE; STROKE; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; TRANSIENT ISCHEMIC ATTACK;

ASPIRIN; DRUG RESISTANCE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; REPRODUCIBILITY OF RESULTS; STROKE;

EID: 39749155679     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.1080/09537100701771736     Document Type: Article

References (43)

1. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
2. Altman R, Luciardi HL, Muntaner J, Herrera RN. The antithrombotic profile of aspirin. Aspirin resistance, or simply failure? Thromb J 2004;2:1-8.
3. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88:230-235.
4. Helgason CM, Tortorice KL, Winkler SR, et al. Aspirin response and failure in cerebral infarction. Stroke 1993;24:345-350.
5. Howard PA. Aspirin resistance. Ann Pharmacother 2002;36:1620-1624.
6. McKee SA, Sane DC, Deliargyris EN. Aspirin resistance in cardiovascular disease: A review of prevalence, mechanisms, and clinical significance. Thromb Haemost 2002;88:711-715.
7. Patrono C. Aspirin resistance: Definition, mechanisms and clinical read-outs. J Thromb Haemost 2003;1:1710-1713.
8. Rocca B, Patrono C. Determinants of the interindividual variability in response to antiplatelet drugs. J Thromb Haemost 2005;3:1597-1602.
9. Hankey GJ, Eikelboom JW. Aspirin resistance. BMJ 2004;328:477-479.
10. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006;367:606-617.
11. Macchi L, Sorel N, Christiaens L. Aspirin resistance: Definitions, mechanisms, prevalence, and clinical significance. Curr Pharm Des 2006;12:251-258.
12. Cattaneo M. Aspirin and clopidogrel: Efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004;24:1980-1987.
13. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41:961-965.
14. Eikelboom JW, Hankey GJ. Aspirin resistance: A new independent predictor of vascular events? J Am Coll Cardiol 2003;41:966-968.
15. Eikelboom JW, Hankey GJ. Failure of aspirin to prevent atherothrombosis: Potential mechanisms and implications for clinical practice. Am J Cardiovasc Drugs 2004;4:57-67.
16. Michelson AD, Cattaneo M, Eikelboom JW, et al. Aspirin resistance: Position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 2005;3:1309-1311.
17. Harrison P. Progress in the assessment of platelet function. Br J Haematol 2000;111:733-744.
18. Harrison P. Platelet function analysis. Blood Rev 2005;19:111-123.
19. Harrison P, Frelinger AL, III, Furman MI, Michelson AD. Measuring antiplatelet drug effects in the laboratory. Thromb Res 2007;120:323-336.
20. Lee PY, Chen WH, Ng W, et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med 2005;118:723-727.
21. Malinin A, Spergling M, Muhlestein B, Steinhubl S, Serebruany V. Assessing aspirin responsiveness in subjects with multiple risk factors for vascular disease with a rapid platelet function analyzer. Blood Coagul Fibrinolysis 2004;15:295-301.
22. Chen WH, Lee PY, Ng W, Tse HF, Lau CP. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004;43:1122-1126.
23. Macchi L, Christiaens L, Brabant S, et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 2002;107:45-49.
24. Alberts MJ, Bergman DL, Molner E, Jovanovic BD, Ushiwata I, Teruya J. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 2004;35:175-178.
25. McCabe DJ, Harrison P, Mackie IJ, et al. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA. Platelets 2005;16:269-280.
26. Harrison P, Segal H, Blasbery K, Furtado C, Silver L, Rothwell PM. Screening for aspirin responsiveness after transient ischemic attack and stroke: Comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke 2005;36:1001-1005.
27. Chakroun T, Addad F, Abderazek F, et al. Screening for aspirin resistance in stable coronary artery patients by three different tests. Thromb Res 2007;Epub ahead of print.
28. Lordkipanidze M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007;28:1702-1708.
29. Cattaneo M. Laboratory detection of 'aspirin resistance': What test should we use (if any)? Eur Heart J 2007;28:1673-1675.
30. Rothwell PM, Coull AJ, Giles MF, et al. Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet 2004;363:1925-1933.
31. Rothwell PM, Coull AJ, Silver LE, et al. Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet 2005;366:1773-1783.
32. Jilma B. Platelet function analyzer (PFA-100): A tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med 2001;138:152-163.
33. Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA. Description of an in vitro platelet function analyzer - PFA-100. Semin Thromb Hemost 1995;21 Suppl 2:106-112.
34. Favaloro EJ. Clinical application of the PFA-100. Curr Opin Hematol 2002;9:407-415.
35. Mammen EF, Comp PC, Gosselin R, et al. PFA-100 system: A new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998;24:195-202.
36. Smith JW, Steinhubl SR, Lincoff AM, et al. Rapid platelet-function assay: An automated and quantitative cartridge-based method. Circulation 1999;99:620-625.
37. Stejskal D, Proskova J, Petrzelova A, et al. Application of cationic propyl gallate as inducer of thrombocyte aggregation for evaluation of effectiveness of antiaggregation therapy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2001;145:69-74.
38. Paniccia R, Antonucci E, Gori AM, et al. Comparison of different methods to evaluate the effect of aspirin on platelet function in high-risk patients with ischemic heart disease receiving dual antiplatelet treatment. Am J Clin Pathol 2007;128:143-149.
39. Stejskal D, Vaclavik J, Lacnak B, Proskova J. Aspirin resistance measured by cationic propyl gallate platelet aggregometry and recurrent cardiovascular events during 4 years of follow-up. Eur J Intern Med 2006;17:349-354.
40. Chen WH, Lee PY, Ng W, et al. Relation of aspirin resistance to coronary flow reserve in patients undergoing elective percutaneous coronary intervention. Am J Cardiol 2005;96:760-763.
41. Chen WH, Cheng X, Lee PY, et al. Aspirin resistance and adverse clinical events in patients with coronary artery disease. Am J Med 2007;120:631-635.
42. Satoh K, Ozaki Y. [Attempts for aspirin monitoring with a new assay system, Ultegra Rapid Platelet Function Assay (RPFA), based on turbidimetric platelet agglutination of whole blood samples]. Rinsho Byori 2006;54:576-582.
43. Fontana P, Nolli S, Reber G, de MP. Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers. J Thromb Haemost 2006;4:813-819.